Delays in Neovasc’s (NSDQ:NVCN) early feasibility trial for its Tiara transcatheter mitral valve implant and declining 1st-quarter profits combined to push its stock price down this week.
(Reuters) — Coloplast (CPH:COLO B) reported a 16% increase in 2nd-quarter core profit, slightly below expectations, pushing the medical device company’s share price down nearly 4%.